Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care

NCT03420430 is registered in ClinicalTrials.gov with Genelux Corporation as lead sponsor.

NCT NCT03420430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03420430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care
Lead sponsor
Genelux Corporation
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (6 patients), advanced stage cancer (solid tumor disease for 4 patients)